Cash Flow Statement (Annual)
TGTX / TG Therapeutics, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities Continuing Operations|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Share Based Compensation||86||3,422||5,203||21,105||15,697||7,510||15,945|
|Noncash Licensing Expense||-||-||-||-||-||-||-|
|Investment Income Amortization Of Premium||-||0||1||194||536||459||61|
|Change In Fair Value Of Notes Payable||0||-816||2,415||-211||57||110||-59|
|Increase Decrease In Operating Capital|
|Increase Decrease In Other Current Assets||-4||1,933||-229||4,563||3,106||-3,564||2,665|
|Increase Decrease In Prepaid Rent||-||-||-||-||-||-||-|
|Increase Decrease In Accrued Interest Receivable Net||-||0||27||58||101||-102||25|
|Increase Decrease In Other Noncurrent Assets||-||0||85||0||42||5||-162|
|Increase Decrease In Other Accounts Payable And Accrued Liabilities||408||596||4,035||-603||5,471||6,493||11,020|
|Increase Decrease In Deferred Rent||-||-||-||-||-||-||-|
|Increase Decrease In Deferred Revenue||0||1,981||-152||-152||-152||-152||-152|
|Net Cash Provided By Used In Operating Activities Continuing Operations||-||-5,188||-10,824||-35,060||-44,690||-61,591||-93,764|
|Net Cash Provided By Used In Investing Activities Continuing Operations|
|Payments To Acquire Property Plant And Equipment||0||1||6||19||42||344||2|
|Payments To Acquire Held To Maturity Securities Short Term||-||-||4,920||18,337||48,994||15,200||28,006|
|Proceeds From Maturities||-||-||0||0||24,350||29,500||19,800|
|Net Cash Provided By Used In Investing Activities Continuing Operations||-||-1||-4,926||-18,355||-24,686||26,545||-8,208|
|Net Cash Provided By Used In Financing Activities Continuing Operations|
|Proceeds From Warrant Exercises||-||0||2,281||3,557||1,067||618||2,143|
|Net Proceeds From Shares New Issues Overallotments||-||-||37,648||65,614||67,761||4,411||131,516|
|Net Cash Provided By Used In Financing Activities Continuing Operations||-||11,897||39,779||68,644||68,724||5,016||133,659|
|Cash And Cash Equivalents Period Increase Decrease||9,748||6,708||24,029||15,228||-652||-30,030||31,687|
|Cash And Cash Equivalents Period Increase Decrease|
|Cash And Cash Equivalents At Carrying Value||9,748||16,456||40,485||55,714||55,061||25,031||56,718|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-|
|Accrued Financing Costs||61||0||0||-||-||-||-|
|Reclassification Of Deferred Financing Costs Toadditional Paidin Capital||-||-||-||-||-||-||-|
Peers - Pharmaceutical Preparations (2834)
ADMP / Adamis Pharmaceuticals Corp.
CAPR / Capricor Therapeutics, Inc.
CPIX / Cumberland Pharmaceuticals Inc.
CRBP / Corbus Pharmaceuticals Holdings, Inc.
CTRV / Contravir Pharmaceuticals Inc
CWBR / CohBar Inc.
CYCC / Cyclacel Pharmaceuticals, Inc.
DFFN / Diffusion Pharmaceuticals Inc.
EDNV / ENDONOVO THERAPEUTICS, INC.
MYOS / MYOS RENS Technology Inc.
NTRP / Neurotrope, Inc.
PRPH / ProPhase Labs, Inc.
PTI / Proteostasis Therapeutics, Inc.
SNDX / Syndax Pharmaceuticals, Inc.
TPIV / TapImmune, Inc.
WVE / WAVE Life Sciences Ltd.
XBIO / Xenetic Biosciences, Inc.
XBIT / XBiotech Inc.
Related News Stories
After its initial hiccup earlier with its CLL drug, this news should bolster the stock a little. (7-0)
Biotech and pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-7)
Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which can spell disaster for a stock, comes great reward as well. Some companies can see massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U. (136-18)
As of late, it has definitely been a great time to be an investor in Tyme Technologies, Inc. (TYME - Free Report) . The stock has moved higher by 22.5% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. (16-0)
Ra Pharmaceuticals, Inc. (RARX - Free Report) has been on the move lately as the stock has risen by 60.8% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue? (16-0)
as of ET